77.36
price up icon1.46%   1.105
 
loading
Illumina Inc stock is traded at $77.36, with a volume of 355.30K. It is up +1.46% in the last 24 hours and down -12.11% over the past month. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$76.25
Open:
$76.75
24h Volume:
355.30K
Relative Volume:
0.14
Market Cap:
$11.64B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-7.7666
EPS:
-9.96
Net Cash Flow:
$546.00M
1W Performance:
+8.65%
1M Performance:
-12.11%
6M Performance:
-45.29%
1Y Performance:
-37.04%
1-Day Range:
Value
$75.53
$77.55
1-Week Range:
Value
$69.83
$79.37
52-Week Range:
Value
$68.70
$156.66

Illumina Inc Stock (ILMN) Company Profile

Name
Name
Illumina Inc
Name
Phone
(858) 202-4500
Name
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Name
Employee
8,970
Name
Twitter
@illumina
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ILMN's Discussions on Twitter

Compare ILMN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
ILMN
Illumina Inc
77.41 11.64B 4.39B -1.58B 546.00M -9.96
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
422.08 164.88B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
195.13 136.41B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
437.11 32.61B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
105.97 29.28B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
149.13 26.17B 15.41B 1.37B 2.11B 7.50

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-04-25 Reiterated Citigroup Neutral
Feb-28-25 Downgrade HSBC Securities Buy → Hold
Feb-10-25 Downgrade Barclays Equal Weight → Underweight
Feb-07-25 Downgrade TD Cowen Buy → Hold
Dec-11-24 Downgrade Citigroup Buy → Neutral
Nov-12-24 Resumed Morgan Stanley Equal-Weight
Oct-17-24 Upgrade HSBC Securities Hold → Buy
Aug-28-24 Upgrade Argus Hold → Buy
Aug-16-24 Upgrade Daiwa Securities Neutral → Buy
Aug-14-24 Upgrade Barclays Underweight → Equal Weight
Aug-14-24 Upgrade TD Cowen Hold → Buy
Jul-10-24 Upgrade Citigroup Neutral → Buy
Jun-03-24 Resumed Jefferies Hold
Jan-16-24 Downgrade HSBC Securities Buy → Hold
Jan-04-24 Downgrade TD Cowen Outperform → Market Perform
Dec-18-23 Upgrade Scotiabank Sector Perform → Sector Outperform
Dec-15-23 Upgrade Bernstein Underperform → Mkt Perform
Dec-14-23 Initiated Guggenheim Buy
Dec-14-23 Initiated Stephens Overweight
Dec-13-23 Initiated Wolfe Research Outperform
Dec-12-23 Downgrade BofA Securities Neutral → Underperform
Dec-11-23 Upgrade Citigroup Sell → Neutral
Nov-10-23 Downgrade Canaccord Genuity Buy → Hold
Sep-28-23 Initiated Bernstein Underperform
Jul-05-23 Resumed JP Morgan Neutral
Jan-25-23 Downgrade Argus Buy → Hold
Jan-05-23 Initiated Scotiabank Sector Perform
Dec-12-22 Downgrade Citigroup Neutral → Sell
Dec-07-22 Initiated RBC Capital Mkts Outperform
Oct-04-22 Upgrade SVB Leerink Mkt Perform → Outperform
Sep-28-22 Upgrade Evercore ISI In-line → Outperform
Aug-25-22 Initiated Credit Suisse Neutral
Jul-13-22 Downgrade Barclays Equal Weight → Underweight
Jan-18-22 Upgrade Stifel Hold → Buy
Jan-11-22 Upgrade Barclays Underweight → Equal Weight
Jan-07-22 Upgrade BofA Securities Underperform → Neutral
Jan-06-22 Resumed Morgan Stanley Equal-Weight
Jan-06-22 Resumed Piper Sandler Overweight
Oct-15-21 Resumed Cowen Outperform
Aug-19-21 Downgrade SVB Leerink Outperform → Mkt Perform
Jun-01-21 Upgrade Evercore ISI Underperform → In-line
Mar-31-21 Downgrade Atlantic Equities Overweight → Neutral
Mar-31-21 Upgrade Canaccord Genuity Hold → Buy
Mar-03-21 Initiated Barclays Underweight
Dec-22-20 Upgrade Piper Sandler Neutral → Overweight
Dec-17-20 Upgrade BTIG Research Neutral → Buy
Oct-13-20 Downgrade Guggenheim Buy → Neutral
Sep-30-20 Initiated Atlantic Equities Overweight
Sep-29-20 Downgrade Wolfe Research Outperform → Peer Perform
Sep-22-20 Downgrade Stifel Buy → Hold
Sep-22-20 Downgrade UBS Buy → Neutral
Sep-21-20 Upgrade Guggenheim Neutral → Buy
Sep-21-20 Downgrade JP Morgan Overweight → Neutral
Sep-09-20 Initiated Morgan Stanley Equal-Weight
Aug-07-20 Downgrade Evercore ISI In-line → Underperform
Aug-07-20 Downgrade Piper Sandler Overweight → Neutral
Jul-07-20 Downgrade Guggenheim Buy → Neutral
Apr-24-20 Downgrade Citigroup Buy → Neutral
Apr-21-20 Downgrade Robert W. Baird Outperform → Neutral
Jan-08-20 Initiated Wells Fargo Underweight
Jan-07-20 Initiated Citigroup Buy
Jan-02-20 Downgrade Evercore ISI Outperform → In-line
Nov-15-19 Initiated Stifel Buy
Oct-25-19 Initiated Guggenheim Buy
View All

Illumina Inc Stock (ILMN) Latest News

pulisher
10:26 AM

It’s all about accessibility: Developing technical training for the MiSeq i100 Series - Illumina

10:26 AM
pulisher
07:57 AM

Should You Hold Illumina (ILMN)? - Yahoo Finance

07:57 AM
pulisher
Apr 23, 2025

Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News

Apr 23, 2025
pulisher
Apr 22, 2025

Resmed Taps Illumina Exec for Chief Investor Relations Officer Role - Medical Product Outsourcing

Apr 22, 2025
pulisher
Apr 22, 2025

Microarray Market Projected To Witness Massive Growth, 2025-2032 | Thermo Fisher Scientific Inc.,Illumina Inc. - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

DNA Microarray Technology Market: Innovations & Opportunities - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Genomic Cancer Testing Market Overall Study Report 2025-2032 | - openPR.com

Apr 22, 2025
pulisher
Apr 21, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 21, 2025
pulisher
Apr 21, 2025

Thomas Kean Jr purchases shares in Illumina and nVent Electric - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Resmed Names Salli Schwartz as Chief Investor Relations Officer - The Manila Times

Apr 21, 2025
pulisher
Apr 21, 2025

Resmed Names Salli Schwartz as Chief Investor Relations Officer - GlobeNewswire Inc.

Apr 21, 2025
pulisher
Apr 21, 2025

Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns - Insider Monkey

Apr 21, 2025
pulisher
Apr 21, 2025

Controlling Genes Market Detailed in New Research Report By 2032 - openPR.com

Apr 21, 2025
pulisher
Apr 18, 2025

Illumina (ILMN) Receives a Buy from Leerink Partners - The Globe and Mail

Apr 18, 2025
pulisher
Apr 18, 2025

Illumina, Tempus AI partner to drive genomic testing beyond cancer - MedTech Dive

Apr 18, 2025
pulisher
Apr 18, 2025

Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks - Yahoo Finance

Apr 18, 2025
pulisher
Apr 17, 2025

DNA Methylation Market Deep Research Report with Forecast by 2032 | Illumina, Inc.,Thermo Fisher Scientific - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

RNA Sequencing Market Size, Share, Outlook, Industry Analysis, - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

MicroRNA Market Size, Share, Trends, Opportunities, - openPR.com

Apr 17, 2025
pulisher
Apr 16, 2025

AI in Omics Studies Market Overall Study Report 2025-2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina - openPR.com

Apr 16, 2025
pulisher
Apr 15, 2025

Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina and Tempus join forces to expand genomic testing By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina, Tempus AI Collaborating to Accelerate Clinical Use of Sequencing Tests - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina and Tempus join forces to expand genomic testing - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation - PR Newswire

Apr 15, 2025
pulisher
Apr 14, 2025

BofA Securities Cuts Price Target on Illumina to $75 From $90, Keeps Underperform Rating - MarketScreener

Apr 14, 2025
pulisher
Apr 13, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Apr 13, 2025
pulisher
Apr 13, 2025

Illumina (NASDAQ:ILMN) Price Target Cut to $112.00 by Analysts at Royal Bank of Canada - MarketBeat

Apr 13, 2025
pulisher
Apr 12, 2025

Illumina : Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development - MarketScreener

Apr 12, 2025
pulisher
Apr 11, 2025

Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent

Apr 11, 2025
pulisher
Apr 10, 2025

Illumina To Announce First Quarter 2025 Financial Results On Thursday, May 8, 2025 - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Shareholders in Illumina (NASDAQ:ILMN) have lost 77%, as stock drops 6.8% this past week - simplywall.st

Apr 10, 2025
pulisher
Apr 10, 2025

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Cancer Profiling Market Positioned for Accelerated Growth with - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Illumina (ILMN) Receives a Sell from Barclays - The Globe and Mail

Apr 10, 2025
pulisher
Apr 09, 2025

Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders - MSN

Apr 09, 2025
pulisher
Apr 09, 2025

Genotyping Assay Market Surges to USD 37.1 Billion by 2029: - openPR.com

Apr 09, 2025
pulisher
Apr 09, 2025

Biotechnology company Illumina names Julie Hiner as comms head - Medical Marketing and Media

Apr 09, 2025
pulisher
Apr 09, 2025

PacBio to cut jobs, lower spending over NIH funding cuts and tariffs - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

DNA Data Storage Market to See Booming Growth 2025-2032 | Illumina, Inc.,Microsoft,Iridia, Inc.,Twist Bioscience - openPR.com

Apr 09, 2025
pulisher
Apr 08, 2025

DNA Sequencing Technologies Market Deep Research Report with - openPR.com

Apr 08, 2025
pulisher
Apr 08, 2025

Admera Health uses the NovaSeq X Plus to expand capabilities - Illumina

Apr 08, 2025
pulisher
Apr 08, 2025

RBC Cuts Price Target on Illumina to $112 From $128, Keeps Outperform Rating - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.

Apr 08, 2025
pulisher
Apr 08, 2025

Where are the Opportunities in (ILMN) - news.stocktradersdaily.com

Apr 08, 2025
pulisher
Apr 07, 2025

Deep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings) - Benzinga

Apr 07, 2025
pulisher
Apr 07, 2025

Apple To $250? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

Apr 07, 2025
pulisher
Apr 07, 2025

How Do Investors Really Feel About Illumina? - Benzinga

Apr 07, 2025

Illumina Inc Stock (ILMN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
diagnostics_research DGX
$173.97
price down icon 0.05%
diagnostics_research LH
$222.92
price down icon 0.56%
diagnostics_research WAT
$328.78
price down icon 1.78%
$149.19
price up icon 3.02%
diagnostics_research MTD
$1,044.96
price up icon 4.17%
diagnostics_research IQV
$146.54
price up icon 2.44%
Cap:     |  Volume (24h):